Use of human MIR135a-3p in preparation of preparations for diagnosing and treating prostate cancer

Abstract

The invention belongs to the biotechnical field, and concretely relates to a new prostate cancer molecule marker microRNA 135a-3p (MIR135a-3p) and a use thereof in the preparation of preparations for diagnosing and treating the prostate cancer. The use comprises the following steps: screening prostate cancer high-risk populations, diagnosing the prostate cancer, designing prostate cancer drug target, monitoring the prostate cancer treatment condition, and carrying out prognosis detection on the prostate cancer. A method using the molecule marker and a diagnostic kit containing the molecule marker to diagnose the prostate cancer has the characteristics of simplicity in operation, convenience in material drawing, good safety, no wounds, high specificity, high sensitivity, and easiness in massive screening.

Description

technical field [0001] The invention belongs to the field of biotechnology, and specifically relates to a new prostate cancer molecular marker MIR135a-3p and its use in preparing preparations for diagnosing and treating prostate cancer, including the screening of high-risk groups of prostate cancer through the biomolecular marker , the diagnosis of prostate cancer, the design of prostate cancer drug targets, the monitoring of prostate cancer treatment status, the monitoring of prostate cancer drug guidance and the detection of prostate cancer prognosis and other fields. Background technique [0002] Existing technologies have disclosed that liquid biopsy technology (according to the relevant content in the "ASCO Annual Report: 2015 Clinical Oncology Advances") is listed as one of the next decade trends in the field of cancer treatment. Studies have shown that some molecular markers in the blood have been used in the diagnosis of some diseases, such as alanine aminotransferas...

AI Technical Summary

Problems solved by technology

For example, the limitations of digital rectal examination mainly lie in four aspects: (1) When the prostate mass is not large, it is easy to miss the diagnosis; (2) Some patients have no obvious prostate cancer, but it is already at an advanced stage, and it is not easy to cure; (3) This test cannot be used when there is a disease in the rectum; (4) Inexperienced doctors may miss or misdiagnose

Under normal circumstances, the PSA in the blood is not high (not higher than 4ng / ml). When in the state of prostate cancer and other prostate diseases, the increase of PSA has become the most sensitive tumor marker for screening prostate cancer, but it also exists Certain limitations: (1) Blood testing is required, which will cause certain damage to the patient; (2) Elevated PSA is also common with non-prostate cancer diseases, such as prostatitis, prostatic hypertrophy, etc., so it is not easy to diagnose; (3) Elevated PSA is diagnosed In the case of prostate cancer, the patients are often in the middle and late stage, and the purpose of early diagnosis cannot be achieved

Ultrasonic detection of the prostate is simple, intuitive, and non-invasive. It provides positioning by displaying the size, number, location, density, edge, shape, presence or absence of calcification, and the shape, size, number, and distribution of calcification, as well as surrounding halos and skin changes. and qualitative signs and judge the nature of the lesion; its limitations are: (1) it is easy to miss the diagnosis of dense small cancer focus; (2) sometimes it cannot provide a clear qualitative diagnosis; (3) because it cannot show the internal structure of the tumor (4) There is a high misdiagnosis rate for some solid benign and malignant masses lacking typical signs

Images